Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 32 | 2024 | 373 | 5.450 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2013 | 24 | 0.980 |
Why?
|
| Breast Feeding | 3 | 2013 | 42 | 0.960 |
Why?
|
| Humans | 67 | 2024 | 29556 | 0.870 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 105 | 0.850 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2023 | 41 | 0.790 |
Why?
|
| Female | 48 | 2024 | 18379 | 0.780 |
Why?
|
| Rural Population | 3 | 2024 | 250 | 0.770 |
Why?
|
| Accidental Falls | 3 | 2017 | 211 | 0.750 |
Why?
|
| United Nations | 1 | 2020 | 4 | 0.720 |
Why?
|
| Electronic Health Records | 3 | 2017 | 121 | 0.710 |
Why?
|
| Statistics as Topic | 1 | 2020 | 107 | 0.690 |
Why?
|
| Anti-HIV Agents | 4 | 2022 | 54 | 0.660 |
Why?
|
| Male | 41 | 2024 | 18012 | 0.620 |
Why?
|
| Guideline Adherence | 1 | 2018 | 111 | 0.600 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2016 | 8 | 0.570 |
Why?
|
| Pharmacists | 1 | 2016 | 19 | 0.560 |
Why?
|
| Water Pollutants, Chemical | 1 | 2016 | 3 | 0.560 |
Why?
|
| Fluorocarbons | 1 | 2016 | 19 | 0.560 |
Why?
|
| Family Practice | 1 | 2016 | 49 | 0.550 |
Why?
|
| Internal Medicine | 1 | 2016 | 45 | 0.550 |
Why?
|
| Trauma Centers | 4 | 2017 | 88 | 0.530 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 75 | 0.530 |
Why?
|
| HIV-1 | 2 | 2012 | 45 | 0.520 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 363 | 0.510 |
Why?
|
| Simian immunodeficiency virus | 1 | 2015 | 1 | 0.510 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 1 | 0.510 |
Why?
|
| AIDS Vaccines | 1 | 2015 | 2 | 0.510 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 163 | 0.500 |
Why?
|
| Adult | 26 | 2024 | 8528 | 0.500 |
Why?
|
| Smoking Cessation | 3 | 2021 | 136 | 0.500 |
Why?
|
| Hospice Care | 1 | 2015 | 13 | 0.500 |
Why?
|
| Advance Care Planning | 1 | 2015 | 11 | 0.500 |
Why?
|
| Terminal Care | 1 | 2015 | 19 | 0.500 |
Why?
|
| Physicians | 1 | 2016 | 136 | 0.490 |
Why?
|
| Primates | 1 | 2015 | 102 | 0.490 |
Why?
|
| Smoking | 4 | 2021 | 441 | 0.480 |
Why?
|
| Analgesics, Opioid | 4 | 2019 | 248 | 0.480 |
Why?
|
| Gonorrhea | 3 | 2022 | 7 | 0.460 |
Why?
|
| Chlamydia Infections | 3 | 2022 | 8 | 0.460 |
Why?
|
| Vaginosis, Bacterial | 2 | 2024 | 6 | 0.460 |
Why?
|
| Prevalence | 7 | 2022 | 910 | 0.430 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 471 | 0.430 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 376 | 0.430 |
Why?
|
| Aged | 16 | 2023 | 9590 | 0.430 |
Why?
|
| Renal Dialysis | 1 | 2015 | 265 | 0.410 |
Why?
|
| Middle Aged | 22 | 2022 | 10936 | 0.410 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 680 | 0.410 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2021 | 14 | 0.400 |
Why?
|
| Patient Transfer | 3 | 2016 | 37 | 0.390 |
Why?
|
| United States | 12 | 2023 | 3693 | 0.390 |
Why?
|
| Alabama | 7 | 2023 | 34 | 0.370 |
Why?
|
| Risk Assessment | 6 | 2019 | 1329 | 0.370 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 3764 | 0.340 |
Why?
|
| West Virginia | 7 | 2017 | 15 | 0.340 |
Why?
|
| Patient Compliance | 2 | 2022 | 213 | 0.330 |
Why?
|
| Risk Factors | 10 | 2022 | 3600 | 0.330 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3144 | 0.320 |
Why?
|
| Computer Simulation | 4 | 2023 | 212 | 0.310 |
Why?
|
| Opioid-Related Disorders | 3 | 2019 | 54 | 0.300 |
Why?
|
| Young Adult | 8 | 2024 | 2431 | 0.270 |
Why?
|
| Exercise | 3 | 2023 | 610 | 0.270 |
Why?
|
| Syphilis | 2 | 2022 | 11 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 1389 | 0.250 |
Why?
|
| Trichomonas Infections | 2 | 2021 | 2 | 0.250 |
Why?
|
| Incidence | 4 | 2022 | 1127 | 0.250 |
Why?
|
| Infant, Newborn | 4 | 2016 | 605 | 0.240 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2024 | 1 | 0.240 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2018 | 156 | 0.240 |
Why?
|
| Hypertension | 2 | 2022 | 918 | 0.230 |
Why?
|
| Seizures | 2 | 2022 | 64 | 0.230 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 116 | 0.230 |
Why?
|
| Quality of Life | 2 | 2020 | 833 | 0.230 |
Why?
|
| Overweight | 3 | 2024 | 261 | 0.230 |
Why?
|
| Infant | 4 | 2016 | 976 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 17 | 0.220 |
Why?
|
| Socioeconomic Factors | 3 | 2023 | 396 | 0.220 |
Why?
|
| Obesity | 5 | 2024 | 1081 | 0.220 |
Why?
|
| Models, Statistical | 1 | 2023 | 164 | 0.220 |
Why?
|
| Adolescent | 8 | 2024 | 3284 | 0.220 |
Why?
|
| Hallucinogens | 1 | 2022 | 12 | 0.210 |
Why?
|
| Periodontitis | 1 | 2022 | 9 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2022 | 1701 | 0.210 |
Why?
|
| Restless Legs Syndrome | 1 | 2021 | 2 | 0.200 |
Why?
|
| Parent-Child Relations | 1 | 2022 | 39 | 0.200 |
Why?
|
| Adiposity | 1 | 2023 | 192 | 0.200 |
Why?
|
| Pilot Projects | 5 | 2023 | 489 | 0.200 |
Why?
|
| Telemedicine | 1 | 2023 | 79 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2021 | 49 | 0.200 |
Why?
|
| Primary Health Care | 3 | 2022 | 183 | 0.190 |
Why?
|
| Antigens, Differentiation | 1 | 2021 | 22 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2024 | 2046 | 0.190 |
Why?
|
| Conversion Disorder | 1 | 2020 | 2 | 0.190 |
Why?
|
| Psychophysiologic Disorders | 1 | 2020 | 4 | 0.190 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 71 | 0.180 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 82 | 0.180 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 32 | 0.180 |
Why?
|
| Stress, Psychological | 2 | 2021 | 210 | 0.170 |
Why?
|
| Prescription Drugs | 1 | 2019 | 16 | 0.170 |
Why?
|
| Health Services Research | 1 | 2019 | 80 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 28 | 0.170 |
Why?
|
| Parathyroid Hormone | 1 | 2018 | 40 | 0.160 |
Why?
|
| SEER Program | 1 | 2018 | 33 | 0.160 |
Why?
|
| Minority Groups | 1 | 2018 | 72 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2018 | 52 | 0.160 |
Why?
|
| Weight Loss | 1 | 2021 | 416 | 0.160 |
Why?
|
| Living Donors | 1 | 2018 | 55 | 0.160 |
Why?
|
| Nicotinic Agonists | 1 | 2018 | 49 | 0.160 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 23 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2019 | 111 | 0.150 |
Why?
|
| Diet | 1 | 2020 | 356 | 0.150 |
Why?
|
| Mothers | 2 | 2022 | 81 | 0.150 |
Why?
|
| Food Preferences | 1 | 2017 | 36 | 0.150 |
Why?
|
| Viral Load | 3 | 2023 | 67 | 0.150 |
Why?
|
| Vitamin D | 1 | 2018 | 175 | 0.150 |
Why?
|
| Homosexuality, Male | 3 | 2022 | 76 | 0.140 |
Why?
|
| Age Factors | 2 | 2017 | 1120 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 441 | 0.140 |
Why?
|
| Medicare | 1 | 2018 | 189 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 209 | 0.140 |
Why?
|
| Transportation of Patients | 1 | 2017 | 21 | 0.140 |
Why?
|
| Sports | 1 | 2017 | 33 | 0.140 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 25 | 0.140 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 48 | 0.140 |
Why?
|
| Hospital Mortality | 2 | 2015 | 190 | 0.140 |
Why?
|
| Comorbidity | 4 | 2021 | 548 | 0.140 |
Why?
|
| Ohio | 1 | 2016 | 55 | 0.140 |
Why?
|
| Nicotine | 1 | 2018 | 158 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2016 | 13 | 0.140 |
Why?
|
| Hospitals, Rural | 1 | 2016 | 11 | 0.130 |
Why?
|
| Triage | 1 | 2016 | 66 | 0.130 |
Why?
|
| Sex Factors | 1 | 2017 | 633 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 62 | 0.130 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 52 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 376 | 0.130 |
Why?
|
| Binomial Distribution | 1 | 2015 | 2 | 0.130 |
Why?
|
| Echocardiography | 1 | 2015 | 141 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 75 | 0.130 |
Why?
|
| Feasibility Studies | 3 | 2023 | 270 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2015 | 40 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2015 | 108 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2016 | 333 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 95 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 137 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 59 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2016 | 156 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 177 | 0.120 |
Why?
|
| Sarcolemma | 1 | 2014 | 4 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 353 | 0.120 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 17 | 0.120 |
Why?
|
| Mitochondria, Heart | 1 | 2014 | 17 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2016 | 152 | 0.120 |
Why?
|
| Malawi | 1 | 2013 | 19 | 0.120 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 15 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 251 | 0.120 |
Why?
|
| Stroke | 1 | 2019 | 552 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 440 | 0.110 |
Why?
|
| Vagina | 2 | 2024 | 49 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 813 | 0.110 |
Why?
|
| Peptide Nucleic Acids | 1 | 2012 | 3 | 0.110 |
Why?
|
| Candidiasis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Candida | 1 | 2012 | 7 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 38 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2012 | 34 | 0.110 |
Why?
|
| Heterosexuality | 2 | 2022 | 13 | 0.100 |
Why?
|
| Milk, Human | 1 | 2011 | 15 | 0.100 |
Why?
|
| Causality | 2 | 2021 | 39 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2021 | 95 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1389 | 0.100 |
Why?
|
| Mass Screening | 2 | 2023 | 228 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 984 | 0.100 |
Why?
|
| Universities | 2 | 2023 | 146 | 0.100 |
Why?
|
| Students | 2 | 2023 | 170 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 522 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2024 | 876 | 0.090 |
Why?
|
| Pregnancy | 2 | 2024 | 825 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 727 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2124 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3128 | 0.070 |
Why?
|
| Animals | 2 | 2015 | 7339 | 0.070 |
Why?
|
| Registries | 2 | 2018 | 280 | 0.070 |
Why?
|
| Logistic Models | 2 | 2019 | 729 | 0.070 |
Why?
|
| Uganda | 1 | 2024 | 8 | 0.060 |
Why?
|
| Fertilization | 1 | 2024 | 4 | 0.060 |
Why?
|
| Gardnerella | 1 | 2024 | 1 | 0.060 |
Why?
|
| Microbial Interactions | 1 | 2024 | 1 | 0.060 |
Why?
|
| Prevotella | 1 | 2024 | 2 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2023 | 16 | 0.060 |
Why?
|
| Cameroon | 1 | 2023 | 4 | 0.060 |
Why?
|
| Weight Gain | 1 | 2024 | 109 | 0.060 |
Why?
|
| Child | 2 | 2022 | 2234 | 0.060 |
Why?
|
| Educational Status | 1 | 2023 | 165 | 0.050 |
Why?
|
| Testosterone | 1 | 2023 | 49 | 0.050 |
Why?
|
| Stavudine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Ritonavir | 1 | 2022 | 3 | 0.050 |
Why?
|
| Integrase Inhibitors | 1 | 2022 | 1 | 0.050 |
Why?
|
| Alkynes | 1 | 2022 | 2 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2022 | 21 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 65 | 0.050 |
Why?
|
| Schools | 1 | 2023 | 65 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2022 | 20 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 54 | 0.050 |
Why?
|
| Social Support | 1 | 2023 | 167 | 0.050 |
Why?
|
| Length of Stay | 2 | 2014 | 296 | 0.050 |
Why?
|
| Sexual Partners | 1 | 2022 | 34 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 19 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 21 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 20 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 165 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 57 | 0.050 |
Why?
|
| Lipids | 1 | 2022 | 215 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2021 | 98 | 0.050 |
Why?
|
| Sleep Deprivation | 1 | 2020 | 8 | 0.050 |
Why?
|
| Motor Activity | 1 | 2023 | 315 | 0.050 |
Why?
|
| Parents | 1 | 2022 | 121 | 0.050 |
Why?
|
| Internal-External Control | 1 | 2020 | 16 | 0.050 |
Why?
|
| Behavior Therapy | 1 | 2021 | 92 | 0.050 |
Why?
|
| Linear Models | 1 | 2021 | 427 | 0.050 |
Why?
|
| Conditioning, Classical | 1 | 2020 | 25 | 0.050 |
Why?
|
| Safety | 1 | 2020 | 73 | 0.050 |
Why?
|
| Attention | 1 | 2020 | 85 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2020 | 35 | 0.040 |
Why?
|
| Self Concept | 1 | 2020 | 42 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 64 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 2014 | 0.040 |
Why?
|
| Walking | 1 | 2020 | 185 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 345 | 0.040 |
Why?
|
| Selection Bias | 1 | 2019 | 13 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 861 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2020 | 120 | 0.040 |
Why?
|
| Minority Health | 1 | 2018 | 7 | 0.040 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 38 | 0.040 |
Why?
|
| HIV | 1 | 2018 | 22 | 0.040 |
Why?
|
| Carbon Monoxide | 1 | 2018 | 7 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 29 | 0.040 |
Why?
|
| Algorithms | 1 | 2021 | 468 | 0.040 |
Why?
|
| Accidents, Traffic | 1 | 2020 | 191 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2018 | 88 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2019 | 115 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 448 | 0.040 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 91 | 0.040 |
Why?
|
| Personal Autonomy | 1 | 2017 | 10 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 638 | 0.040 |
Why?
|
| Bone Density | 1 | 2018 | 183 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 93 | 0.040 |
Why?
|
| Observation | 1 | 2016 | 24 | 0.040 |
Why?
|
| Health Status | 1 | 2018 | 373 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2015 | 33 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 126 | 0.030 |
Why?
|
| Health Behavior | 1 | 2017 | 217 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2016 | 141 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 88 | 0.030 |
Why?
|
| Diastole | 1 | 2015 | 91 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 328 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 171 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 365 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 293 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 178 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 158 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 796 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2014 | 22 | 0.030 |
Why?
|
| Body Height | 1 | 2014 | 31 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2014 | 116 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2016 | 469 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2015 | 282 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 1172 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2012 | 161 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2014 | 803 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 94 | 0.030 |
Why?
|
| Mice | 1 | 2015 | 2387 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1372 | 0.020 |
Why?
|